Skip to main content

Table 2 Univariate and multivariate analysis of potential prognostic factors at initial brain irradiation

From: Population-based outcomes after whole brain radiotherapy and re-irradiation in patients with metastatic breast cancer in the trastuzumab era

 

Univariable Analysis

Multivariable Analysis

Characteristics

HR (95% CI)

pvalue

HR (95% CI)

pvalue

RPA at diagnosis of BM

    

   1

1 [Reference]

 

1 [Reference]

 

   2

1.92 (1.30-2.82)

< 0.001

1.55 (1.00-2.40)

0.05

   3

5.23 (3.50-7.80)

< 0.001

4.24 (2.66-6.73)

< 0.001

SRS boost at initial BM

    

   Yes

1 [Reference]

 

1 [Reference]

 

   No

3.05 (1.71-5.44)

< 0.001

2.94 (1.51-5.73)

0.002

Craniotomy

    

   Yes

1 [Reference]

 

1 [Reference]

 

   No

2.87 (2.15-3.84)

< 0.001

2.70 (1.89-3.85)

< 0.001

Number of lesions

    

   1

1 [Reference]

 

1 [Reference]

 

   2-3

1.31 (0.91-1.89)

0.139

1.19 (0.82-1.72)

0.36

   > 3

2.18 (1.66-2.88)

< 0.001

1.02 (0.78-1.34)

0.88

HER2 status

    

   Positive

1 [Reference]

 

1 [Reference]

 

   Negative and Equivocal

1.74 (1.39-2.18)

< 0.001

1.55 (1.09-2.20)

0.015

Chemotherapy at BM

    

   Yes

1 [Reference]

 

1 [Reference]

 

   No

2.26 (1.81-2.84)

< 0.001

1.81 (1.41-2.33)

< 0.001

Hormonal therapy at BM

    

   Yes

1 [Reference]

 

1 [Reference]

 

   No

1.64

< 0.001

2.22 (1.66-2.97)

< 0.001

Trastuzumab at initial BM

    

   Yes

1 [Reference]

 

1 [Reference]

 

   No

1.74 (1.37-2.20)

< 0.001

1.37 (0.94-2.01)

0.100

  1. Abbreviations: RPA = recursive partitioning analysis, SRS = stereotactic radiosurgery, HER2 = human epidermal growth factor receptor 2, BM = brain metastasis
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us